-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Jiangsu clearly makes dynamic adjustments to the "dual-channel" management and separate payment list according to the adjustment of the national medical insurance list
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
Recently, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Adjusting the "Dual-Channel" Management and Separate Payment of Some Guotan Drugs, which clarifies that the following adjustments will be made to the management methods of some Guotan drugs from May 1, 2022:
Six drugs, including Trastuzumab Injection, Bevacizumab Injection, Adalimumab Injection, Raltitrexed Injection, Erlotinib Oral Regular Release Form, and Deferasirox Oral Regular Release Form, were adjusted and adjusted.
A separate payment list will be published, and dual-channel management will continue to be retained
.
A separate payment list will be published, and dual-channel management will continue to be retained
.
The Eltrombopag ethanolamine tablets in the national medical insurance negotiation drug list were transferred to the "dual-channel" management and separate payment list
.
.
The icotinib hydrochloride tablets in the national medical insurance negotiation drug list were transferred from the "dual-channel" management to the "dual-channel" management and separate payment list
.
.
The scope of adjusted drugs includes generic drugs and biosimilar drugs with the same generic name and the same dosage form of the medical insurance list
.
.
Jiangsu has made it clear that it will dynamically adjust the "dual channel" management and separate payment list
On July 20, 2021, the Jiangsu Provincial Medical Insurance Bureau and the Jiangsu Provincial Health and Health Commission jointly issued the "Implementation Opinions on Establishing and Improving the "Dual-Channel" Management Mechanism for National Medical Insurance Negotiated Drugs", which clarified that the classified management of national medical insurance negotiation drugs will be divided into " "Dual-channel" managed drugs and conventional Class B managed drugs
.
.
Include the varieties and innovative drugs with high clinical value, urgent needs of patients, and low substitution among Guotan drugs into the "dual-channel" management.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
On April 20, 2022, the Jiangsu Medical Insurance Bureau issued a document to dynamically adjust the "dual-channel" management and separate payment list according to the results of the dynamic adjustment of the National Drug List
.
.
1.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
The newly added "National Drugs" with high clinical value, urgently needed by patients, and low-substitute varieties and innovative drugs will be included in the "dual-channel" management
.
.
According to the affordability of the fund, priority will be given to the drugs and innovative drugs with long use cycles and high treatment costs that are included in the "dual-channel" management, and will be included in separate payment
.
.
2.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
For the negotiated drugs that have not been successfully renewed in the national medical insurance drug list after the expiration of the "National Drug Talk" agreement, the "dual-channel" management and separate payment drug list will be simultaneously transferred;
After the expiration of the "Guotan Drugs" agreement, the original "Guotan Drugs" that were transferred to the regular catalogue and belonged to the province's current "Dual-channel" management list of drugs for separate payment, withdraw from the separate payment and retain the "Dual-channel" management
.
.
The "Notice" clearly adheres to the basic principles of affordability of funds, connection of benefits, fairness and justice, and carries out "dual-channel" management and transfer-in and transfer-out of separate payment lists
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
At present, Jiangsu Province has also adjusted the relevant catalogues many times.
On February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
On February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
On April 14, 2022, the icotinib hydrochloride tablets in the Guotan catalogue were transferred to the "dual-channel" management and separate payment catalogue
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
Publish documents in multiple places to dynamically adjust the "dual-channel" management catalog of medical insurance
Not only Jiangsu, but many provinces have issued documents to make dynamic adjustments to the medical insurance "dual-channel" management catalog, while Jiangxi, Shanxi, Xinjiang and other provinces have adjusted the scope of "dual-channel" drugs
.
.
On January 29, 2022, Shanxi issued a document to add 36 drugs, including icatibant acetate injection, among the new negotiated drugs in the country in 2021, and eltrombopag ethanolamine tablets and avamaleate among the negotiated drugs during the agreement period.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Sevelamer and lanthanum carbonate are no longer managed as special drugs and are included in the scope of outpatient chronic and special diseases
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
On March 7, 2022, Jiangxi Medical Insurance Bureau issued a document that upon the independent application of drug manufacturers , it is planned to transfer "sodium zirconium cyclosilicate powder" to the list of dual-channel drugs, and manage it according to the national medical insurance negotiation drug category
B.
B.
On April 15, 2022, Xinjiang issued a document to dynamically adjust the "dual-channel" management of special drug catalogs and drug identification standards :
Adjustment of bevacizumab combination drug payment coverage
.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
Adjust the certification materials required for drugs according to the actual situation of Xinjiang inspection
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
Newly added drugs for hepatolenticular degeneration
.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
Adjust part of the drug treatment evaluation cycle according to the actual situation
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
Jiangsu clearly makes dynamic adjustments to the "dual-channel" management and separate payment list according to the adjustment of the national medical insurance list
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
Recently, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Adjusting the "Dual-Channel" Management and Separate Payment of Some Guotan Drugs, which clarifies that the following adjustments will be made to the management methods of some Guotan drugs from May 1, 2022:
Six drugs, including Trastuzumab Injection, Bevacizumab Injection, Adalimumab Injection, Raltitrexed Injection, Erlotinib Oral Regular Release Form, and Deferasirox Oral Regular Release Form, were adjusted and adjusted.
A separate payment list will be published, and dual-channel management will continue to be retained
.
A separate payment list will be published, and dual-channel management will continue to be retained
.
The Eltrombopag ethanolamine tablets in the national medical insurance negotiation drug list were transferred to the "dual-channel" management and separate payment list
.
.
The icotinib hydrochloride tablets in the national medical insurance negotiation drug list were transferred from the "dual-channel" management to the "dual-channel" management and separate payment list
.
.
The scope of adjusted drugs includes generic drugs and biosimilar drugs with the same generic name and the same dosage form of the medical insurance list
.
.
Jiangsu has made it clear that it will dynamically adjust the "dual channel" management and separate payment list
On July 20, 2021, the Jiangsu Provincial Medical Insurance Bureau and the Jiangsu Provincial Health and Health Commission jointly issued the "Implementation Opinions on Establishing and Improving the "Dual-Channel" Management Mechanism for National Medical Insurance Negotiated Drugs", which clarified that the classified management of national medical insurance negotiation drugs will be divided into " "Dual-channel" managed drugs and conventional Class B managed drugs
.
.
Include the varieties and innovative drugs with high clinical value, urgent needs of patients, and low substitution among Guotan drugs into the "dual-channel" management.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
On April 20, 2022, the Jiangsu Medical Insurance Bureau issued a document to dynamically adjust the "dual-channel" management and separate payment list according to the results of the dynamic adjustment of the National Drug List
.
.
1.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
The newly added "National Drugs" with high clinical value, urgently needed by patients, and low-substitute varieties and innovative drugs will be included in the "dual-channel" management
.
.
According to the affordability of the fund, priority will be given to the drugs and innovative drugs with long use cycles and high treatment costs that are included in the "dual-channel" management, and will be included in separate payment
.
.
2.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
For the negotiated drugs that have not been successfully renewed in the national medical insurance drug list after the expiration of the "National Drug Talk" agreement, the "dual-channel" management and separate payment drug list will be simultaneously transferred;
After the expiration of the "Guotan Drugs" agreement, the original "Guotan Drugs" that were transferred to the regular catalogue and belonged to the province's current "Dual-channel" management list of drugs for separate payment, withdraw from the separate payment and retain the "Dual-channel" management
.
.
The "Notice" clearly adheres to the basic principles of affordability of funds, connection of benefits, fairness and justice, and carries out "dual-channel" management and transfer-in and transfer-out of separate payment lists
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
At present, Jiangsu Province has also adjusted the relevant catalogues many times.
On February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
On February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
On April 14, 2022, the icotinib hydrochloride tablets in the Guotan catalogue were transferred to the "dual-channel" management and separate payment catalogue
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
Publish documents in multiple places to dynamically adjust the "dual-channel" management catalog of medical insurance
Not only Jiangsu, but many provinces have issued documents to make dynamic adjustments to the medical insurance "dual-channel" management catalog, while Jiangxi, Shanxi, Xinjiang and other provinces have adjusted the scope of "dual-channel" drugs
.
.
On January 29, 2022, Shanxi issued a document to add 36 drugs, including icatibant acetate injection, among the new negotiated drugs in the country in 2021, and eltrombopag ethanolamine tablets and avamaleate among the negotiated drugs during the agreement period.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Sevelamer and lanthanum carbonate are no longer managed as special drugs and are included in the scope of outpatient chronic and special diseases
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
On March 7, 2022, Jiangxi Medical Insurance Bureau issued a document that upon the independent application of drug manufacturers , it is planned to transfer "sodium zirconium cyclosilicate powder" to the list of dual-channel drugs, and manage it according to the national medical insurance negotiation drug category
B.
B.
On April 15, 2022, Xinjiang issued a document to dynamically adjust the "dual-channel" management of special drug catalogs and drug identification standards :
Adjustment of bevacizumab combination drug payment coverage
.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
Adjust the certification materials required for drugs according to the actual situation of Xinjiang inspection
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
Newly added drugs for hepatolenticular degeneration
.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
Adjust part of the drug treatment evaluation cycle according to the actual situation
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
Jiangsu clearly makes dynamic adjustments to the "dual-channel" management and separate payment list according to the adjustment of the national medical insurance list
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
.
The newly added "Guotan Drugs" will be included in the scope to be transferred, and the drugs that have expired and have been transferred to regular catalog management and the negotiated drugs that have not been successfully renewed after the expiration of the agreement will be included in the scope of transfer
.
Recently, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Adjusting the "Dual-Channel" Management and Separate Payment of Some Guotan Drugs, which clarifies that the following adjustments will be made to the management methods of some Guotan drugs from May 1, 2022:
Six drugs, including Trastuzumab Injection, Bevacizumab Injection, Adalimumab Injection, Raltitrexed Injection, Erlotinib Oral Regular Release Form, and Deferasirox Oral Regular Release Form, were adjusted and adjusted.
A separate payment list will be published, and dual-channel management will continue to be retained
.
A separate payment list will be published, and dual-channel management will continue to be retained
.
The Eltrombopag ethanolamine tablets in the national medical insurance negotiation drug list were transferred to the "dual-channel" management and separate payment list
.
.
The icotinib hydrochloride tablets in the national medical insurance negotiation drug list were transferred from the "dual-channel" management to the "dual-channel" management and separate payment list
.
.
The scope of adjusted drugs includes generic drugs and biosimilar drugs with the same generic name and the same dosage form of the medical insurance list
.
.
Jiangsu has made it clear that it will dynamically adjust the "dual channel" management and separate payment list
On July 20, 2021, the Jiangsu Provincial Medical Insurance Bureau and the Jiangsu Provincial Health and Health Commission jointly issued the "Implementation Opinions on Establishing and Improving the "Dual-Channel" Management Mechanism for National Medical Insurance Negotiated Drugs", which clarified that the classified management of national medical insurance negotiation drugs will be divided into " "Dual-channel" managed drugs and conventional Class B managed drugs
.
.
Include the varieties and innovative drugs with high clinical value, urgent needs of patients, and low substitution among Guotan drugs into the "dual-channel" management.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
Among them, drugs with long use cycles and high treatment costs and innovative drugs are given priority.
According to the affordability of the fund, Implement a separate payment policy
.
On April 20, 2022, the Jiangsu Medical Insurance Bureau issued a document to dynamically adjust the "dual-channel" management and separate payment list according to the results of the dynamic adjustment of the National Drug List
.
.
1.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
Include the newly added "Guotan Drugs" in the new National Catalogue (including the drugs transferred into the Negotiated Drug Catalog from the regular catalogue) into the scope to be transferred
.
The newly added "National Drugs" with high clinical value, urgently needed by patients, and low-substitute varieties and innovative drugs will be included in the "dual-channel" management
.
.
According to the affordability of the fund, priority will be given to the drugs and innovative drugs with long use cycles and high treatment costs that are included in the "dual-channel" management, and will be included in separate payment
.
.
2.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
Include the drugs whose negotiation agreement has expired and have been transferred to conventional catalog management, as well as the negotiated drugs that have not been successfully renewed after the expiration of the agreement, into the scope to be transferred out
.
For the negotiated drugs that have not been successfully renewed in the national medical insurance drug list after the expiration of the "National Drug Talk" agreement, the "dual-channel" management and separate payment drug list will be simultaneously transferred;
After the expiration of the "Guotan Drugs" agreement, the original "Guotan Drugs" that were transferred to the regular catalogue and belonged to the province's current "Dual-channel" management list of drugs for separate payment, withdraw from the separate payment and retain the "Dual-channel" management
.
.
The "Notice" clearly adheres to the basic principles of affordability of funds, connection of benefits, fairness and justice, and carries out "dual-channel" management and transfer-in and transfer-out of separate payment lists
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
.
"Dual-channel" management and separate payment of drugs are subject to generic name management
.
"Dual-channel" management and adjustment of the list of separate payments, in principle, according to the adjustment cycle of the national drug list once a year
.
At present, Jiangsu Province has also adjusted the relevant catalogues many times.
On February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
high blood pressure high blood pressureOn February 14, 2022, Jiangsu issued a document to transfer thiopefilgrastim injection to the "dual-channel" management and separate payment list
.
Sacubitril and Valsartan Sodium Tablets do not implement "dual-channel" management and pay separately for the treatment of essential hypertension
.
On April 14, 2022, the icotinib hydrochloride tablets in the Guotan catalogue were transferred to the "dual-channel" management and separate payment catalogue
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
.
Eltrombopag ethanolamine tablets were transferred to the "dual-channel" management and separate payment list
.
Publish documents in multiple places to dynamically adjust the "dual-channel" management catalog of medical insurance
Not only Jiangsu, but many provinces have issued documents to make dynamic adjustments to the medical insurance "dual-channel" management catalog, while Jiangxi, Shanxi, Xinjiang and other provinces have adjusted the scope of "dual-channel" drugs
.
.
On January 29, 2022, Shanxi issued a document to add 36 drugs, including icatibant acetate injection, among the new negotiated drugs in the country in 2021, and eltrombopag ethanolamine tablets and avamaleate among the negotiated drugs during the agreement period.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Eight drugs, including Tropopa and Riluzole in the Class B list of medical insurance, are included in the scope of special drugs in Shanxi Province
.
Sevelamer and lanthanum carbonate are no longer managed as special drugs and are included in the scope of outpatient chronic and special diseases
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
.
A total of 139 special drugs have been adjusted, and 36 of the nationally negotiated drugs are included in the scope of outpatient chronic and special disease drugs, and other countries' negotiated drugs are managed as ordinary Class B drugs
.
On March 7, 2022, Jiangxi Medical Insurance Bureau issued a document that upon the independent application of drug manufacturers , it is planned to transfer "sodium zirconium cyclosilicate powder" to the list of dual-channel drugs, and manage it according to the national medical insurance negotiation drug category
B.
enterprise enterprise enterpriseB.
On April 15, 2022, Xinjiang issued a document to dynamically adjust the "dual-channel" management of special drug catalogs and drug identification standards :
standard standard standard Adjustment of bevacizumab combination drug payment coverage
.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
tumor tumor tumor.
Octreotide acetate microspheres for injection are suitable for acromegaly, denosumab (60mg) is limited to severe osteoporosis (60mg) in postmenopausal women, and the payment scope of "dual-channel" special drugs for malignant tumors is adjusted
.
Adjust the certification materials required for drugs according to the actual situation of Xinjiang inspection
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
.
Amend the "Test report of HIV-RNA < 50cop/ml can be optionally provided" for Icogen Bacterium Tablets and Bicoempravir Tablets to "The test report of HIV-RNA can be optionally provided"
.
Newly added drugs for hepatolenticular degeneration
.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
medicines medicines medicines.
Added drugs for the treatment of hepatolenticular degeneration : penicillamine, sodium dimercaptopropanesulfonate, dimercaptosuccinic acid
.
Adjust part of the drug treatment evaluation cycle according to the actual situation
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
.
Adjust the evaluation cycle of riluzole treatment from once a month to once every 3 months
.
